Physician profile
Feras Mohder
NPI 1235517582
$4,703.99
in general payments reported to CMS, 2019-2025
28 companies · $1,727 in 2025
The $1,727 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2022: $36.01 · 2023: $560 · 2024: $2,268 · 2025: $1,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,554.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $627.61 | 2022-2024 | Xarelto |
| Janssen Biotech, INC. | $534.67 | 2023-2025 | Rybrevant, Carvykti, Erleada |
| Boston Scientific Corporation | $365.69 | 2024 | Ams 700, Lithovue, Rezum Generator |
| Coloplast Corp | $343.03 | 2024 | |
| Novo Nordisk INC | $248.74 | 2025 | Wegovy |
| Antares Pharma, INC. | $244.81 | 2025 | Xyosted |
| Urogen Pharma, INC. | $156.37 | 2024 | |
| Glaxosmithkline, LLC. | $146.70 | 2022-2024 | Shingrix |
| Phathom Pharmaceuticals, INC. | $130.39 | 2024 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $127.00 | 2025 | Caplyta |
| Inspire Medical Systems, INC. | $126.65 | 2024 | Inspire |
| Calliditas Therapeutics US INC. | $125.00 | 2025 | Tarpeyo |
| Idorsia Pharmaceuticals US INC | $124.87 | 2023 | Quviviq |
| Eisai INC. | $122.03 | 2025 | |
| Blue Earth Diagnostics | $118.75 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laborie Medical Technologies Corp. | $118.37 | 2025 | Endosheath Technology |
| Bayer Healthcare Pharmaceuticals INC. | $118.30 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $117.71 | 2019-2024 | Lifevest |
| Scpharmaceuticals INC. | $115.32 | 2025 | |
| Neurocrine Biosciences, INC. | $102.29 | 2024 | Ingrezza |
| Merck Sharp & Dohme LLC | $101.05 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $100.23 | 2025 | Farxiga |
| Neurelis, INC. | $93.14 | 2024 | Valtoco |
| Mallinckrodt Hospital Products INC. | $90.54 | 2025 | Acthar |
| Shionogi INC | $87.17 | 2025 | Fetroja |
| Pfizer INC. | $77.63 | 2023 | |
| Becton, Dickinson and Company | $20.94 | 2025 | Magic3 Go Intermittent Urinary Catheter |
| Medtronic, INC. | $18.99 | 2024 | Interstim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Feras Mohder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.